Carisma Therapeutics Inc. (Nasdaq: CARM), a US-based clinical-stage biopharmaceutical company, announced on Monday that it has named John Hohneker, MD as its new director.
Dr Hohneker has more than 30 years of extensive experience in drug development and leadership across the biotech and pharmaceutical sectors. Most recently, he served as president and chief executive officer of Anokion SA. He has also worked as the president of Research and Development at FORMA Therapeutics Inc and in roles of increasing responsibility at Novartis AG, which includes most recently as senior vice president and global head of Development, Immunology, and Dermatology. He has also served in positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. Presently, he serves as the director of Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics, Inc. He has earlier served as a member of the board of directors of Torque Therapeutics, Inc., Dimension Therapeutics, Inc., Cygnal Therapeutics, Inc., BioTheryX Inc., Evelo Biosciences, Inc., Humanigen, Inc. and Aravive, Inc.
Sanford Zweifach, chair of the Carisma board of directors, said, 'We are pleased to welcome John to the Carisma board of directors. I believe John's extensive track record of clinical development, strategic leadership, and public company board membership in the biopharmaceutical space will enable him to immediately support the company as it continues leading the field of engineered macrophage development.'
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration